At a glance
ClinicalIndex Comparison Record- ✓Young Mania Rating Scale (YMRS) score greater than 14
- ✓Must be an inpatient
- ✕History of opioid abuse or dependence
- ✕Recent history of substance abuse
- ✕Pregnancy
- ✕Unstable medical conditions
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inpatient Clinical Trial Examining the Effects of Pentazocine on Manic Symptoms
In Brief
A Phase 2 clinical trial evaluating Talwin Nx for Bipolar Disorder. Completed, enrolled 10 participants.
Detailed Summary
The opiate neurotransmitter system is thought to be involved in many abnormal mood states. Some researchers have suggested that changes in this system may trigger the switch to/from manic and depressive states in bipolar disorder. One problem with most of the currently available opiate medications is that they can produce addiction/dependence. A particular kind of opiate medication known as kappa-opiates may be able to produce changes in this system with much less risk of addiction. This study looks at Talwin (a combination of pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The study will examine whether two doses of Talwin affect manic symptoms in people who have been admitted to the hospital. This study will give more information about the involvement of the opiate system in bipolar disorder, and give important information for use in developing new treatments.
Study Details
Timeline
Interventions
Talwin NX 50mg po twice